secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173983
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Taysha stockholders approve reverse stock split and authorized share reduction
------------------------------------------------------------------------------

- Reverse stock split authorized with ratio range of 1:5 to 1:20; 43.1M for, 10.5M against.
- Authorized shares reduction (formula based on split ratio) approved: 43.3M for, 10.2M against.
- Both directors elected: Sean P. Nolan (35.6M for) and Laura Sepp-Lorenzino (33.6M for).
- Ratification of Deloitte as auditor: 53.5M for, 51k against.
- Broker non-votes of 14.3M on director elections; no broker non-votes on other proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/0001193125-23-173983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523173983/d242570d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer